Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

The Lancet Oncology - Tập 14 Số 10 - Trang 933-942 - 2013
David Cameron1, Julia Brown2, Rebecca Dent3,4, Christian Jackisch5, John R. Mackey6, Xavier Pivot7, Guenther G. Steger8, Thomas Suter9, Masakazu Toi10, Mahesh Parmar11, R. Laeufle12, Young‐Hyuck Im13, Gilles Romieu14, Vernon Harvey15, Oleg Lipatov16, Tadeusz Pieńkowski17, Paul Cottu18, Arlene Chan19, Seock‐Ah Im20, Peter Hall21, Lida Bubuteishvili‐Pacaud12, Volkmar Henschel12, Regula Deurloo12, Céline Pallaud12, Richard H. Bell22
1University of Edinburgh and Cancer Services, NHS Lothian, Edinburgh, UK
2Clinical Trials Research Unit, University of Leeds, Leeds, UK
3Department of Medical Oncology, National Cancer Center, Singapore, Singapore
4Sunnybrook Health Sciences Center and University of Toronto, Toronto, ON, Canada
5Department of Obstetrics and Gynecology and Breast Cancer Center, Klinikum Offenbach, Offenbach, Germany
6Cross Center Institute, Edmonton, AL, Canada
7Service Oncologie Medicale, University Hospital Jean Minjoz, Besançon, France
8Department of Internal Medicine, Division of Oncology, Medical University of Vienna, Vienna, Austria
9Swiss Cardiovascular Center, Bern University Hospital, Inselspital, Bern, Switzerland
10Faculty of Medicine, Kyoto University, Kyoto, Japan > > > > > >
11Medical Research Council Clinical Trials Unit, London, UK
12F. Hoffmann-La Roche Ltd, Basel, Switzerland
13Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
14Institut du Cancer Montpellier, Val d'Aurelle, France
15Regional Cancer and Blood Centre, Auckland City Hospital, Auckland, New Zealand
16Republican Clinical Oncology Dispensary, Ufa, Russia
17Postgraduate Medical Center, Warsaw, Poland
18Department of Medical Oncology, Institut Curie, Paris, France
19Curtin University, Breast Cancer Research Centre-WA, Perth, Australia
20Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
21Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
22Andrew Love Cancer Centre, Geelong, Australia

Tóm tắt

Từ khóa


Tài liệu tham khảo

Dent, 2007, Triple-negative breast cancer: clinical features and patterns of recurrence, Clin Cancer Res, 13, 4429, 10.1158/1078-0432.CCR-06-3045

Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med, 357, 2666, 10.1056/NEJMoa072113

Brufsky, 2012, Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial, Breast Cancer Res Treat, 133, 1067, 10.1007/s10549-012-2008-6

von Minckwitz, 2012, Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer, N Engl J Med, 366, 299, 10.1056/NEJMoa1111065

Bear, 2012, Bevacizumab added to neoadjuvant chemotherapy for breast cancer, N Engl J Med, 366, 310, 10.1056/NEJMoa1111097

Foekens, 2001, High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer, Cancer Res, 61, 5407

Holmgren, 1995, Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression, Nat Med, 1, 149, 10.1038/nm0295-149

Miles, 2013, Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer, Br J Cancer, 108, 1052, 10.1038/bjc.2013.69

Claudon, 2008, New automated multiplex assay for bone turnover markers in osteoporosis, Clin Chemistry, 54, 1554, 10.1373/clinchem.2008.105866

Hudis, 2007, Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system, J Clin Oncol, 25, 2127, 10.1200/JCO.2006.10.3523

Van Cutsem E, Jayson G, Dive C, et al. Analysis of blood plasma factors in the AVITA phase III randomized study of bevacizumab (bev) with gemcitabine-erlotinib (GE) in patients (pts) with metastatic pancreatic cancer (mPC). European Multidisciplinary Cancer Congress, 23–27 September 2011, Stockholm, Sweden (abstr 803).

Van Cutsem, 2012, Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial, J Clin Oncol, 30, 2119, 10.1200/JCO.2011.39.9824

Gianni, 2012, Biomarker (BM) results from the phase III AVEREL trial of 1st-line bevacizumab (BV), trastuzumab (H) + docetaxel (T) for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC), Ann Oncol, 23, ix531, 10.1016/S0923-7534(20)34201-0

Cortes, 2012, Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis, Ann Oncol, 23, 1130, 10.1093/annonc/mdr432

Wagner, 2012, Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer, Cochrane Database Syst Rev, 7, 10.1002/14651858.CD008941.pub2

Ranpura, 2011, Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis, JAMA, 305, 487, 10.1001/jama.2011.51

Choueiri, 2011, Congestive heart failure risk in patients with breast cancer treated with bevacizumab, J Clin Oncol, 29, 632, 10.1200/JCO.2010.31.9129

Miller, 2012, Bevacizumab (B) in the adjuvant treatment of breast cancer – first toxicity results from Eastern Cooperative Oncology Group trial E5103, Cancer Res, 72, 462s

Allegra, 2011, Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08, J Clin Oncol, 29, 11, 10.1200/JCO.2010.30.0855

de Gramont, 2012, Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial, Lancet Oncol, 13, 1225, 10.1016/S1470-2045(12)70509-0

Seymour, 2012, Adjuvant bevacizumab in colon cancer: where did we go wrong?, Lancet Oncol, 13, 1176, 10.1016/S1470-2045(12)70521-1

Van Cutsem, 2011, Lessons from the adjuvant bevacizumab trial on colon cancer: What next?, J Clin Oncol, 29, 1, 10.1200/JCO.2010.32.2701

Oyan, 2012, Why do targeted agents not work in the adjuvant setting in colon cancer?, Expert Rev Anticancer Ther, 12, 1337, 10.1586/era.12.111

Prat, 2013, Molecular characterization of basal-like and non-basal-like triple-negative breast cancer, Oncologist, 18, 123, 10.1634/theoncologist.2012-0397

Thông tin
Thông tin xuất bản

The Lancet Oncology

Tập 14 Số 10

933-942

Thông tin tác giả